In AML CDX models, CD19 CAR T cells that secrete CD19-BP–targeting CLEC12A exhibited the similar anti-tumor activity to CLEC12A-targeting CAR T cells (48). This evidence concerns the gene CD19 and acute myeloid leukemia.